PharmSource - Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity

Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. A significant difference in manufacturing status emerged between products originally discovered in-house and those in-licensed from external partners. During this period 66% of in-licensed NMEs were either outsourced completely or partially, compared to 44% for internally discovered candidates.

Reasons to buy

According to the latest PharmSource Trend Report, Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity, in-licensing of NMEs is an important positive signal to the CDMO sector that a candidate is likely to be successful and its manufacture is likely to be outsourced.

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

I use GlobalData on an almost daily basis.

  International Investment Firm